You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信达生物(01801.HK)与和黄医药拓展合作 开展药品实体瘤联合治疗临床评估
阿思达克 10-10 16:24

信达生物(01801.HK)公布,与和黄医药进一步拓展双方的全球临床合作,共同评估信达生物的重组全人源抗PD-1单克隆抗体达伯舒(信迪利单抗注射液),与和黄医药的索凡替尼(一种新型血管内皮生长因子受体及成纤维细胞生长因子受体1抑制剂,同时抑制集落刺激因子-1受体)联合治疗晚期实体瘤患者的安全性和有效性。

两家公司是次合作是在现有的全球合作协议,即共同评估信迪利单抗与和黄医药的高选择性血管内皮生长因子受体抑制剂基础上进一步扩展合作范围。

信达生物与和黄医药进一步拓展全球临床合作可让双方共同就达伯舒与索凡替尼针对实体瘤中未满足的临床需求进行共同探索和开发。新组合的临床研究将在美国和中国进行。达伯舒和索凡替尼的联合疗法有望通过同时针对肿瘤微环境中的多种细胞类型和信号传导途径而带来协同的抗癌作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account